VistaPharm Recalls Nystatin Oral Suspension Due to Impurity Exceeding Specifications
VistaPharm is recalling Nystatin Oral Suspension because an impurity peak exceeded approved specifications. The affected product is distributed in the United States and Puerto Rico.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this recall as Class III, which by definition is unlikely to cause adverse health consequences, aligning with the 'Low' severity criteria for documentation or minor specification issues.
Plain-English summary
VistaPharm, Inc. is recalling 14,760 bottles of Nystatin Oral Suspension, USP 100,000 units per mL, Bubblegum Flavored, 16 fl. oz. bottle (480 mL). The product is identified by Lot # 639000 and has an expiration date of 10/31/2021. The recall is due to the presence of an impurity peak that exceeds the approved specification.
The affected product was distributed in the United States, including Puerto Rico. The FDA has classified this recall as Class III, which indicates that use of or exposure to the product is not likely to cause adverse health consequences.
Consumers who have this product should stop using it and contact their healthcare provider or pharmacist for further instructions. The product is prescription-only (Rx Only).
The recalled product
- Product
- Nystatin Oral Suspension, USP 100,000 units per mL, Bubblegum Flavored, 16 fl. oz. bottle (480 mL), Shake Well Before Using, Rx Only, Manufactured by: VistaPharm, Inc., Largo, FL 33771, NDC 66689-008-16.
- Manufacturer
- VistaPharm, Inc.
- Category
- Drug — Antifungal
- Hazard
- Affected units
- 14,760
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 639000
- Exp. 10/31/2021
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 2 recalled by VistaPharm, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · VistaPharm, Inc.
See all →- ModeratePrescription pyridostigmine bromide oral solution recalled for out-of-specification preservative
FDA (Drugs) · 2022-11-02
- ModerateClobazam Oral Suspension Recalled for Failed Stability Specifications
FDA (Drugs) · 2022-01-26
- LowVistaPharm Recalls Nystatin Oral Suspension Due to Impurity
FDA (Drugs) · 2020-10-14
- LowVistaPharm Recalls Nystatin Oral Suspension Due to Impurity Peak
FDA (Drugs) · 2020-07-15
- LowVistaPharm Recalls Nystatin Oral Suspension Due to Impurity Failures
FDA (Drugs) · 2018-12-26
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17